Yposkesi, a Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapies, has announced the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat patients living with rare and life-threatening diseases.
Project SKY will create approximately 80 new jobs by 2023. The French facility, designed for European and American GMP compliance, will double Yposkesi’s production capacity and allow it to address the shortage in manufacturing capacity for drug developers seeking to advance clinical trials and commercialise new therapeutic drugs.
“Yposkesi is proud and excited to embark full speed on this new phase in our development. SKY is the culmination of our industrial strategy, guaranteeing clients a range of quality services from early clinical drug development through all phases to the manufacture of large-scale commercial batches of ATMPs,” said Alain Lamproye, Executive Chairman of Yposkesi. “This project will also showcase our outstanding technological know-how in bioproduction for gene therapy drugs.”
